Result:Weak· Market: Flat#Margin expansion#Cost led
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 57.12 | 15.1% | 0.4% |
| Total Income | 57.23 | 15.1% | 0.2% |
| Expenditure | 63.98 | 20.7% | 9.1% |
| PBT | -6.75 | 49.2% | 48.1% |
| Net Profit | -7.64 | 43.1% | 44.6% |
| OPM | 1.58% | 9.93pp | 9.39pp |
| NPM | -13.35% | 6.57pp | 10.71pp |
| EPS | 4.83 | 43.0% | 44.6% |
Pharma: revenue stayed flat YoY (-0.4%) and the company remains in a net loss despite a smaller deficit, so core growth is absent even though cost control narrowed losses.
Informational and educational content only. Not investment advice.